New Breast Density Treatment May Have Fewer Side Effects, Lower Cancer Risk

Recent research has unveiled encouraging results for a potential breast cancer prevention drug, (Z)-endoxifen. This treatment has been shown to effectively decrease mammographic breast density while exhibiting fewer side effects compared to the well-known drug tamoxifen, which is commonly used in breast cancer prevention.

A significant concern for women over 40 is breast density, which affects nearly half of this demographic and is linked to increased breast cancer risk. The KARISMA Endoxifen trial, published in the Journal of the National Cancer Institute, investigated the effects of (Z)-endoxifen on breast density, aiming to identify a safer alternative to existing therapies.

The study involved 240 premenopausal women, aged 40 to 55, who were recruited from Sweden’s national breast cancer screening program. These participants were randomly assigned to receive either a placebo, 1 milligram (mg), or 2 mg of (Z)-endoxifen for six months. A double-blind design ensured that neither the participants nor the researchers knew which treatment was administered until the trial’s conclusion, minimizing bias.

Researchers measured mammographic breast density, a known indicator of breast cancer risk, through digital mammograms taken at the beginning, three months in, and at the end of the six-month period. The assessment utilized advanced technology to ensure accuracy and reliability of results.

The findings were promising: both doses of (Z)-endoxifen led to a significant reduction in breast density compared to the placebo group, with the 1 mg dose resulting in a 19.3% decrease and the 2 mg dose achieving a 26.5% reduction. This reduction in density mirrors the results achieved with the standard 20 mg dose of tamoxifen, suggesting that lower doses of (Z)-endoxifen could be just as effective.

While the safety profile was similar across all groups, those taking the 1 mg dose experienced fewer side effects. Commonly reported side effects included irregular menstrual cycles, night sweats, and hot flashes, but the higher dose was associated with more severe symptoms. Notably, participants taking the lower dose reported fewer instances of gastrointestinal issues, vaginal bleeding, and other discomforts.

Experts believe these results are significant for breast cancer prevention strategies. Dr. Blen Tesfu, a medical advisor, emphasized that the lower dose’s effectiveness could enhance patient compliance with long-term hormone-based therapies, which is often a challenge due to side effects associated with existing treatments like tamoxifen.

Brian Clark, a certified registered nurse anesthetist, pointed out that many women who struggle with tamoxifen’s side effects do not receive adequate preventive care. The introduction of (Z)-endoxifen could expand access to essential treatment for those populations.

However, it is important to note that this trial is still in its initial stages, and further research is needed to confirm whether (Z)-endoxifen can effectively reduce breast cancer risk over a longer term. If validated, this treatment could provide a more manageable and effective option for women at risk for breast cancer, potentially improving outcomes and quality of life.